Description: Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
Home Page: www.celyad.com
CYAD Technical Analysis
Axis Business Park
Mont-Saint-Guibert,
1435
Belgium
Phone:
32 1 039 41 00
Officers
| Name | Title |
|---|---|
| Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME | Co-Founder, CFO, Interim CEO & Director |
| Mr. David Georges | VP of Fin. & Admin. |
| Sara Zelkovic | Communications & Investor Relations Director |
| Mr. Philippe Nobels | Chief HR Officer & VP of HR |
| Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. | Chief Medical Officer |
| Ms. An Phan | Head of Legal |
| Mr. Hannes Iserentant | Head of Intellectual Property |
| Dr. Frédéric Lehmann | VP of Clinical Devel. & Medical Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6921 |
| Price-to-Sales TTM: | 12738.134 |
| IPO Date: | 2015-06-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 95 |